BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/15/2026 6:47:28 AM | Browse: 117 | Download: 281
 |
Received |
|
2025-10-14 14:40 |
|
Peer-Review Started |
|
2025-10-14 14:41 |
|
First Decision by Editorial Office Director |
|
2025-12-02 08:16 |
|
Return for Revision |
|
2025-12-02 08:16 |
|
Revised |
|
2025-12-08 13:27 |
|
Publication Fee Transferred |
|
2025-12-18 13:31 |
|
Second Decision by Editor |
|
2026-02-10 02:46 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-10 08:11 |
|
Articles in Press |
|
2026-02-10 08:11 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-01 00:36 |
|
Publish the Manuscript Online |
|
2026-04-15 06:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Ming Huang, Xiao-Bo Zhang, Jing Li, Guo-Hui Zhang, Xiao Zhang, Ying-Tian Wei, Hui Sun, Li Ma, Zhen-Jun Wang, Di-Xiao Yao, Hong-Jian Shi, Ti Wang and Yue-Yong Xiao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yue-Yong Xiao, Department of Radiology, The First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. fszdk_301@163.com |
| Key Words |
Liver cancer; High-frequency irreversible electroporation; Programmed death-1/programmed death-ligand 1 inhibitor; Toll-like receptor 7/8 agonist; Antitumor immunity |
| Core Tip |
High-frequency irreversible electroporation potently triggers immunogenic cell death within tumors. In combination with BMS-1 and R848, this multimodal strategy not only curbs tumor progression but also dynamically reprograms the immunosuppressive tumor microenvironment. Specifically, it augments the infiltration of CD3+ CD4+ and CD3+ CD8+ T cells, CD11c+ CD80+ CD86+ dendritic cells, and F4/80+ CD11b+ CD86+ M1 macrophages, while depleting immunosuppressive subsets such as CD4+ CD25+ FOXP3+ regulatory T cells and F4/80+ CD11b+ CD206+ M2 macrophages. Consequently, the regimen induces a pronounced abscopal effect and fosters robust, systemic antitumor immunity, underscoring its translational potential as an innovative combination immunotherapy. |
| Publish Date |
2026-04-15 06:47 |
| Citation |
Huang SM, Zhang XB, Li J, Zhang GH, Zhang X, Wei YT, Sun H, Ma L, Wang ZJ, Yao DX, Shi HJ, Wang T, Xiao YY. High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity. World J Gastroenterol 2026; 32(15): 115226
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i15/115226.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i15.115226 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
